Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for...
Sihuan Pharmaceutical
Sihuan Pharmaceutical Restructures with Dual Organization Model
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a...
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
Sihuan Pharma’s Fourth-Gen Insulin Degludec NDA Accepted by NMPA for Review
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its New Drug Application (NDA)...
Sihuan Pharma’s Anaprazole Enters Phase II Study for Reflux Esophagitis
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its subsidiary Xuanzhu Biopharmaceutical Co.,...
Sihuan Pharma to Sell Generic Drug Businesses, Shift Focus to Aesthetics and Biologics
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of...